The top 100 stock
market authors
selected for publication
market authors
selected for publication
AstraZeneca plc (AZN) ()
|
|
|
| 52wk high: | |
| 52wk low: | |
| EPS: | |
| PE: | |
| Dividend: | |
| Yield: | |
| Market Cap: | |
| Exchange: |
Articles on AstraZeneca plc (AZN) by latest | most commented
- Generic Players Continue to Impress in H1
- Closing Update for Wednesday, July 1
- FDA Calendar Updates: AspenBio, CytRx, Cephalon, Pozen, Sanofi, AMAG
- AstraZeneca’s Pipeline Must Deliver
- 30 Possible Pandemic Profit Plays: Bullish Biotech and Drug Stocks to Watch
- FDA Calendar Updates: AZN, BMY, OSUR, CPD, INSM, HLUKY
- Santarus: Business Fundamentals Are Unchanged
- ADR Overview - Which Stocks Look Good, Which Don't
- 15 Possible Healthcare Breakout Stocks
- Global Pharma Outlook Negative as Patents Expire
- Companies Involved in the Treatment of Swine Flu
- Six Solid Dividend Payers That Look Attractive
- The 30 Best U.S. Traded International Dividend Stocks
- Astra Zeneca Short Base Still High, But Declining
- Life Science Companies Get Boost from Capital Markets
- FDA Calendar Updates: ABT, AFFY, AZN, LLY, MELA, PFE, SOMX, VPHM
- Merck and AstraZeneca: An Uncommon Deal Indeed
- FDA, Clinical Trial Calendars: Cancer Drug Updates from ASCO
- The Imperatives of Healthcare Reform
- China: Latest Hotspot for Western Biotech, Pharma Firms
- Latest Trend Leaders
- Bad News for Drugmakers: UAW Retires Viagra and Nexium
- FDA, Clinical Trial Updates: Insmed, Jazz Pharma Await Key Results
- High Yield Blue Chips Set to Rally?
- FDA, Clinical Trial Calendar Updates: AstraZeneca Announces Phase III Results
- AstroZeneca: Brilinta News Not a Panacea
- Vanda Pharmaceuticals: Tomorrow's Headline Stock
- 22 Dividend Stocks with Good Fundamentals
- Now's the Time to Add Dividend Stocks to Your Portfolio
- FDA Calendar Updates: AstraZeneca, GlaxoSmithKline, Sanofi-Aventis
- Pharmaceutical Stocks Remain a Buy
- Possible Swine Flu Profit Trades
- FDA Calendar Updates: Diabetes
- Buy British or Buy American?
- 3 Simple Guidelines for Investing in Retailers
- Updated FDA, Clinical Trial Calendars: Myriad Pharma Announces Phase 1 Trial
- Bristol-Myers Squibb: An Attractive Value
- FDA Calendar Updates: Santarus, Cephalon, AstraZeneca, Dendreon, Gilead, Novo Nordisk
- 10 Top British Mutual Fund Holdings
- FDA and Clinical Trial Updates: Weight Loss, Diabetes and More
- Which Diabetes Drugs Will Win Out?
-
The Seeking Alpha 100
See all
Seeking Alpha 100 » -
Fastest Climbers
Authors with the largest
increase in followers
in the last 7 days-
1
Philip Davis
-
2
David Fry
-
3
Bill Gross
-
4
TraderMark
-
5
Tyler Durden
Fastest Climbers » -
1
-
Top Commenters
Top commenters,See all
as ranked by their peers
Top Commenters » -
Top Instabloggers
The 100 most activeSee all
Instabloggers.
Top Instabloggers » -
Top StockTalkers
TopSee all
StockTalkers.
Top StockTalkers »
